Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Ke‑Jun Nan"'
Autor:
Xiao-Hui Jia, Lu-Ying Geng, Pan-Pan Jiang, Hong Xu, Ke-Jun Nan, Yu Yao, Li-Li Jiang, Hong Sun, Tian-Jie Qin, Hui Guo
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-17 (2020)
Abstract The enthusiasm for immune checkpoint inhibitors (ICIs), an efficient tumor treatment model different from traditional treatment, is based on their unprecedented antitumor effect, but the occurrence of immune-related adverse events (irAEs) is
Externí odkaz:
https://doaj.org/article/6f815d564a234245917fc383534284af
Autor:
Tao Wu, Xiao-An Ma, Guo-Qing Wang, Qing Li, Miao-Jing Li, Jin-Yue Guo, Xuan Liang, Zhi-Ping Ruan, Tao Tian, Ke-Jun Nan, Li-Na Liu, Hui Guo
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract ABO blood types are associated with the prognosis of several malignancies. However, the role of the ABO blood type in hepatocellular carcinoma (HCC) remains elusive. Here, we evaluated the prognostic role of the ABO blood group in 691 HCC pa
Externí odkaz:
https://doaj.org/article/e06dff3a0e9a4247bdae3a23950e9a9f
Autor:
Tao Tian, Chun-Li Li, Xiao Fu, Shu-Hong Wang, Jun Lu, Hui Guo, Yu Yao, Ke-Jun Nan, Yu-Juan Yang
Publikováno v:
Journal of International Medical Research, Vol 46 (2018)
Objective To explore the role and mechanism of β1 integrin in the regulation of multicellular drug resistance in hepatocellular carcinoma (HCC). Methods This in vitro study used a liquid overlay technique to obtain multicellular spheroids of two hum
Externí odkaz:
https://doaj.org/article/b90a430c2c9a4c18a71068ac9159b7e9
Publikováno v:
PLoS ONE, Vol 12, Iss 9, p e0184160 (2017)
The number of elderly patients diagnosed with hepatocellular carcinoma (HCC) is expected to increase. The present study aims to evaluate the role of age on treatments and outcome of HCC patients. 1530 patients firstly diagnosed with HCC were retrospe
Externí odkaz:
https://doaj.org/article/4767b3a6d97b4ef6b6aee47b49075d1c
Autor:
Wen-Juan Wang, Yu Yao, Li-Li Jiang, Ting-Hua Hu, Jie-Qun Ma, Zi-Jun Liao, Jun-Tao Yao, Dong-Fan Li, Shu-Hong Wang, Ke-Jun Nan
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76596 (2013)
Expression of lymphoid enhancer factor 1 (LEF1) is frequently altered in different human cancers. This study aimed to assess LEF1 expression in colon cancer tissues and to explore changed phenotypes, gene expressions, and the possible mechanism after
Externí odkaz:
https://doaj.org/article/44628f71c2b749d5a0b7b1cb8892538f
Autor:
Ming Li, Ya‑Huan Guo, Shu-Hong Wang, Zheng Zhao, Hai‑Feng Sun, Li Jing, Ke‑Jun Nan, Tao Wu, Min‑Cong Wang, Hui Guo
Publikováno v:
Oncology Letters
Delisheng is a widely used antineoplastic agent in China. Although previous studies revealed that Delisheng exhibits numerous pharmacological effects including the inhibition of cancer cell differentiation and enhancement of immune function with the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b806bfc980ab5583941bdedcbe4b49f5
https://doi.org/10.3892/ol.2017.7074
https://doi.org/10.3892/ol.2017.7074
Autor:
Lili Han, Jing Wang, Tao Wu, Qianqian Guo, Jie Cui, Zhi‑Yan Liu, Li Jing, Ke‑Jun Nan, Yu Yao, Lili Jiang, Ying Liu, Jie‑Qun Ma, Xuan Liang, Cheng‑Cheng Yang, Min‑Cong Wang
Publikováno v:
Oncology Reports. 33:239-249
The concurrent administration of chemotherapy and epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) has previously produced a negative interaction and failed to confer a survival benefit to non‑small cell lung cancer (NSCL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd9ea4f80f49303f0ec245490e56dc7
https://doi.org/10.3892/or.2014.3583
https://doi.org/10.3892/or.2014.3583
Autor:
Jie Jun Wang, Yong Yu Liu, Yiping Zhang, Wei Lian Li, Qi Tao Yu, Feng Zhan Qin, Jin Wan Wang, Ke Jun Nan, Xiaoqing Liu, Hou Jie Liang, Chen Yao, Jing Min Zhou, Kai Li, Yuan Rong Tu, Wei Liu, Qing Hua Zhou, Hui Shan Lu, Zheng Tang Chen, Wen Chao Liu, Qiang Chen, Yan Sun, Shu Ping Song, Li Yan Xu, Xiu Wen Wang, Su Xia Luo
Publikováno v:
Thoracic Cancer. 4:440-448
Background: Phase II-III trials in patients with untreated and previously treated locally advanced or non-small cell lung cancer (NSCLC) suggested that Endostar was able to enhance the effect of platinum-based chemotherapy (NP regimen) with tolerable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::402c3e25825278723b3f3a99cdf153c9
https://doi.org/10.1111/1759-7714.12050
https://doi.org/10.1111/1759-7714.12050
Autor:
Yi Lv, Tao Tian, Ting Hua Hu, Lili Jiang, Zhi Ping Ruan, Hui Guo, Xin Sui, Ke Jun Nan, Wen Juan Wang
Publikováno v:
Carcinogenesis. 32:1897-1904
p57 is a multifunctional protein involved in the regulation of tumor formation and development; however, the biological role of p57 in the pathogenesis of hepatocellular carcinoma (HCC) is poorly understood. To explore the role of p57 in the developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::788b4c2caf81ed2aa958be2b48c60914
https://doi.org/10.1093/carcin/bgr220
https://doi.org/10.1093/carcin/bgr220
Publikováno v:
Anti-Cancer Drugs. 19:931-939
Amphibians have been found to be a source of agents with anticancer properties. Bufalin, for example, is an anticancer agent that may induce apoptosis by its interaction with other genes and cellular components. Certain peptides with anticancer activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d631fa1cee23f0ed90b8795bb6e4139
https://doi.org/10.1097/cad.0b013e3283139100
https://doi.org/10.1097/cad.0b013e3283139100